Skip to content
Biotechnology

CIL Announces Breakthrough in Benzene Recovery, Addressing Cost, Environmental, and Supply Challenges for OLED Display Manufacturers

Cambridge Isotope Laboratories, Inc. 2 mins read

TEWKSBURY, MA / ACCESSWIRE / December 12, 2024 / Cambridge Isotope Laboratories, Inc. (CIL) has successfully developed and implemented a game-changing benzene-d6 recovery program, addressing major pain points for manufacturers of organic light-emitting diode (OLED) displays. This innovative service reduces costs, minimizes environmental impact, and conserves scarce deuterium supplies.

OLED display producers rely heavily on deuterated benzene (benzene-d6) as a critical starting material in their synthesis processes. However, this results in significant quantities of depleted benzene-d6, which is no longer usable but still retains considerable deuterium value. The disposal of such depleted material poses environmental challenges and substantial expenses.

CIL's benzene-recovery program offers a transformative solution. Customers can now return their depleted benzene-d6 to CIL, where it undergoes a proprietary re-enrichment process to restore it to virgin material quality. This service is available at a significant cost savings compared to new benzene-d6, providing significant economic benefits.

Beyond the financial advantages, the program has far-reaching environmental and supply implications. It eliminates the need for costly disposal, reduces the demand on increasingly scarce deuterium (derived from heavy water, D2O) and conserves this vital resource for its growing applications in science, medical diagnostics, pharmaceuticals, and semiconductor production.

Recycling offers several sustainable benefits. It reduces pollution by releasing fewer chemicals into the environment. Recycling also saves energy, as reprocessing chemicals like benzene requires less energy than producing them from raw materials. This leads to lower greenhouse gas emissions, helping to combat climate change.

"This initiative underscores CIL's commitment to collaboration and innovation in addressing our customers' most pressing challenges," said Cliff Caldwell, CEO of CIL. "By recovering and re-enriching depleted benzene-d6, we create a circular economy approach that is both economically and environmentally sustainable. As the world's largest supplier of benzene-d6, we are uniquely positioned to deliver this groundbreaking service."

CIL's benzene recovery program is the result of 12 months of dedicated development, expansion, and rigorous testing to ensure reliable capacity and uncompromising quality. CIL invites interested parties to inquire about the program's details and how to participate.

About Cambridge Isotope Laboratories, Inc.

CIL is the world's largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL subsidiary ABX, located in Dresden, Germany, is active in the development and commercialization of radio isotopic-labeled compounds for the diagnosis and treatment of cancers. CIL is an operating business owned by Otsuka Pharmaceutical. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France. For more information on CIL, visit isotope.com.

Contact Information

Crissy Krisko
crissyk@isotope.com
1.978.269.1930

.

SOURCE: Cambridge Isotope Laboratories, Inc.



View the original press release on accesswire.com

More from this category

  • Biotechnology
  • 21/01/2025
  • 10:39
OncoSil Medical Limited (ASX:OSL)

OncoSil Medical Appoints Lel Smits as Non-Executive Director

Pancreatic cancer treatment device companyOncoSil Medical Limited (ASX:OSL) has announced the appointment of Ms. Lel Smits as a NonExecutive Director to the Board of OncoSil Medical, effective immediately. Ms. Smits brings a wealth of expertise in governance, strategy, risk oversight, and corporate communications, with a distinguished career advising over 500 ASX-listed management teams and Boards. Ms.Smits is an award-winning entrepreneur and director, recognised as Director of the Year by Women in Finance in both 2024 and 2022. Since 2021, she has served as a Director on the Board of Australian Shareholders' Association. Her extensive career began as a finance journalist,…

  • Biotechnology
  • 21/01/2025
  • 08:42
OncoSil Medical Limited (ASX:OSL)

OncoSil Medical Appoints Lel Smits as Non-Executive Director

Pancreatic cancer treatment device companyOncoSil Medical Limited (ASX:OSL) has announced the appointment of Ms. Lel Smits as a NonExecutive Director to the Board of OncoSil Medical, effective immediately. Ms. Smits brings a wealth of expertise in governance, strategy, risk oversight, and corporate communications, with a distinguished career advising over 500 ASX-listed management teams and Boards. Ms.Smits is an award-winning entrepreneur and director, recognised as Director of the Year by Women in Finance in both 2024 and 2022. Since 2021, she has served as a Director on the Board of Australian Shareholders' Association. Her extensive career began as a finance journalist,…

  • Biotechnology
  • 13/01/2025
  • 23:40
X4 Pharmaceuticals

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered, double-digit royalties up to the mid-twentiesUpfront non-dilutive funds strengthen X4’s balance sheet as enrollment ramps up in the company’s global Phase 3 clinical trial in chronic neutropenia Agreement underscores Norgine’s commitment to bring transformative therapies to patients in need in these key strategic territoriesBOSTON and UXBRIDGE, United Kingdom, Jan. 13, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, and Norgine,…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.